Akshat Jain Explores a New Blood Journals Study on the Bleeding Burden in Type 1 VWD
Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared on LinkedIn:
”Novel Bispecific Nanobody
New study out in Blood Journals Portfolio on addressing the bleeding burden in Type 1 VWD patients and development of novel therapy options for these patients via SubCutanous route!
American Society of Hematology
KB-V13A12 is designed to increase the patient’s own von Willebrand factor (VWF) levels by bridging VWF to albumin, potentially enhancing VWF survival in the bloodstream.
KB-V13A12 is a bispecific nanobody that binds both VWF and albumin, aiming to harness the recycling pathway of albumin to protect and maintain higher circulating VWF levels.
In laboratory experiments, the nanobody efficiently tethered VWF to albumin without interfering with VWF’s ability to bind Factor VIII or function in clot formation.
In VWD type 1 mouse models, a single subcutaneous dose of KB-V13A12 led to a rapid, dose-dependent increase in VWF levels—up to 2.1-fold—for up to two weeks.
This elevation translated to significantly improved bleeding control in treated mice, using established bleeding models.”
Read the full article in Blood.
Article: A bispecific nanobody for the treatment of von Willebrand disease type 1
Authors: Ivan Peyron, Caterina Casari, Geneviève McCluskey, Vincent Licari, Emilie Bocquet, Claire Auditeau, Mélanie Y. Daniel, Stéphanie Roullet, Sophie Susen, Olivier D. Christophe, Peter J. Lenting, Cécile V. Denis
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 12, 2026, 20:44Honoring Marion Stolte’s Lasting Impact on the Bleeding Disorders Community – WFH
-
Mar 12, 2026, 20:37Paul Riley: Is Thrombin Generation Assay Ready for Prime Time?
-
Mar 12, 2026, 20:28Rob Maloney: Building Visibility for Bleeding Disorders in Rural Georgia
-
Mar 12, 2026, 20:19Akshat Jain: Validating Oral Pain Medication Use as a Global Marker in Sickle Cell Disease
-
Mar 12, 2026, 20:13Michael Makris: Early Clinical Results of AAV8-BDD FVIII Gene Therapy in Hemophilia A
-
Mar 12, 2026, 20:02Wolfgang Miesbach: From Heparin to Vaccines – The Expanding Biology of Anti-PF4 Immunothrombosis
-
Mar 12, 2026, 19:56Christophe Dubois: Celebrating Nicolas Gendron’s HDR Defense and Future in Hemostasis
-
Mar 12, 2026, 17:06Caitlin Raymond: Managing Crigler–Najjar Syndrome Type 1 Crisis Without a Standard TPE Protocol
-
Mar 12, 2026, 17:03Jan Sloves: Insights on Comprehensive Venous Duplex Imaging at VEITH Symposium 2025